Concepedia

Hongjing Zang

HZ

Statistics

Publications

23

Citations

766

H-Index

16

Active since

2016

Affiliations

Second Xiangya Hospital of Central South University(Current)

Central South University

Xiangya Hospital Central South University

Emory University

Winship Cancer Institute

Hongjing Zang is an author at Second Xiangya Hospital of Central South University specializing in molecular oncology, medicine, and oncology.

ORCID

Publications per year

2016–2025

23

Publications

23

USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1

Jinghua Pan, Yiting Qiao, Congcong Chen et al. · Cell Death and Disease · 2021 · 76 citations · Full text

, , +17

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Lei Zhu, Zhen Chen, Hongjing Zang et al. · Cancer Research · 2021 · 67 citations · Full text

, , +17

CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway

Qiuyuan Wen, Weiyuan Wang, Jiadi Luo et al. · Oncotarget · 2016 · 57 citations · Full text

, , +17

Suppression Of β-catenin Nuclear Translocation By CGP57380 Decelerates Poor Progression And Potentiates Radiation-Induced Apoptosis in Nasopharyngeal Carcinoma

Weiyuan Wang, Qiuyuan Wen, Jiadi Luo et al. · Theranostics · 2017 · 55 citations · Full text

, , +17

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib

Yiting Li, Hongjing Zang, Guoqing Qian et al. · Cancer · 2019 · 52 citations · Full text

, , +17

1–5 of 23